3rd Quarter - Report

ZIMMER BIOMET, INC. for ZIMMER BIOMET, INC.

Firm
Client
Income
—
Expenses
$147,775
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent reform, HR 1249 and S 23

LobbyistCovered position, as disclosed
CHRISTOPHER A CERONE —
WHITNEY TULL —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1249 (112th)

Trade (domestic/foreign) TRD

KORUS FTA

LobbyistCovered position, as disclosed
CHRISTOPHER A CERONE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Health Issues HCR

FDA 510k reform and Medical Device User Fees and PPACA (health care law) implementation and Musculoskeletal Health Disparties Summit in D.C.

LobbyistCovered position, as disclosed
CHRISTOPHER A CERONE —
WHITNEY TULL —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Medical device tax repeal, S 17, S 262, HR 436, HR 488, HR 736 Corporate tax reform

LobbyistCovered position, as disclosed
CHRISTOPHER A CERONE —
WHITNEY TULL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 736 (112th), H.R. 488 (112th), H.R. 436 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.